Jan 03, 2019 8:02am EST Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference
Dec 10, 2018 7:00am EST Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC
Nov 30, 2018 7:00am EST Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
Nov 20, 2018 7:00am EST Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
Oct 31, 2018 7:00am EDT Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
Oct 25, 2018 7:00am EDT Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
Oct 18, 2018 7:00am EDT Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018
